Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name MDM2 amp
Gene Variant Detail

MDM2 amp (no effect)

Relevant Treatment Approaches MDM2 Inhibitor

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
MDM2 amp neuroendocrine tumor predicted - sensitive MDM2 Inhibitor Milademetan Case Reports/Case Series Actionable In a Phase I trial, Milademetan demonstrated safety and preliminary activity in patients with advanced solid tumors, and resulted in prolonged stable disease in 2 patients with MDM2-amplified tumors, 1 with liposarcoma and 1 with carcinoid tumor (J Clin Oncol 34, 2016 (suppl; abstr 2581; NCT01877382). detail...
MDM2 amp urinary bladder cancer no benefit Atezolizumab Case Reports/Case Series Actionable In a clinical case study, a patient with metastatic bladder cancer that harbored MDM2 amplification and other mutations quickly progressed after receiving Tecentriq (atezolizumab), resulting in new liver metastasis and a 258% increase of existing liver metastasis size 1.9 months after treatment (PMID: 28351930). 28351930
MDM2 amp triple-receptor negative breast cancer no benefit Pembrolizumab Case Reports/Case Series Actionable In a clinical case study, a patient with triple-receptor negative breast cancer that harbored MDM2 amplification quickly progressed after receiving Keytruda (pembrolizumab), resulted in new chest wall metastasis and a 55% increase of existing lung metastasis size 1.5 months after treatment (PMID: 28351930). 28351930
MDM2 amp endometrial stromal sarcoma no benefit Nivolumab Case Reports/Case Series Actionable In a clinical case study, a patient with endometrial stromal sarcoma that harbored MDM2 amplification quickly progressed after receiving Opdivo (nivolumab), resulted in new abdominal metastasis and a 242% increase of existing liver metastasis size within 1.5 months of treatment (PMID: 28351930). 28351930
MDM2 amp Advanced Solid Tumor no benefit N/A Clinical Study Emerging In a clinical study, 100% (5/5) of solid tumor patients harboring MDM2 amplification experienced disease progression within 2 months of anti-PD1/PD-L1 monotherapy, indicating a risk for hyperprogression on immunotherapy (PMID: 28351930). 28351930
MDM2 amp liposarcoma predicted - sensitive GDC-0575 + Gemcitabine Preclinical - Cell line xenograft Actionable In a preclinical study, GDC-0575 and Gemzar (gemcitabine) synergistically induced apoptosis and cell cycle arrest in liposarcoma cells harboring MDM2 amplification in culture, and inhibited tumor growth, prolonged progression-free survival in cell line xenogrft models (PMID: 29409053). 29409053
MDM2 amp liposarcoma predicted - sensitive MDM2 Inhibitor unspecified MDM2 inhibitor Phase I Actionable In a Phase I trial, treatment with an unspecified MDM2 inhibitor resulted in clinical efficacy in six patients with liposarcoma harboring MDM2 amplification, including three patients with a partial response and two patients with stable disease for 15.7 months and 4.7 months (PMID: 30237864). 30237864
MDM2 amp dedifferentiated liposarcoma predicted - sensitive MDM2 Inhibitor BI 907828 Preclinical - Pdx Actionable In a preclinical study, BI 907828 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of dedifferentiated liposarcoma harboring MDM2 amplification (PMID: 31201607). 31201607
MDM2 amp liposarcoma predicted - sensitive MDM2 Inhibitor BI 907828 Case Reports/Case Series Actionable In a Phase I trial, BI 907828 treatment led to a partial response in 3 of 7 patients with liposarcoma, all responders harbored MDM2 amplification (Ann Oncol 32 (2021): S1294; NCT03449381). detail...
MDM2 amp dedifferentiated liposarcoma sensitive MDM2 Inhibitor Milademetan Phase I Actionable In a Phase I trial, Milademetan treatment resulted in an objective response rate of 3.8% (2/53, 2 partial responses), a disease control rate of 58.5%, and a median progression-free survival of 7.2 months in patients with dedifferentiated liposarcoma, 100% (22/22) of the patients tested for MDM2 had MDM2 amplification (CN > 6) with a median CN of 28.6 (PMID: 36669146; NCT01877382). 36669146
MDM2 amp well-differentiated liposarcoma not applicable N/A Clinical Study Diagnostic MDM2 amplification aids in the diagnosis of well-differentiated liposarcoma (PMID: 33799733, PMID: 34984861, PMID: 35074968, PMID: 36674856). 36674856 33799733 34984861 35074968
MDM2 amp dedifferentiated liposarcoma not applicable N/A Clinical Study Diagnostic MDM2 amplification aids in the diagnosis of dedifferentiated liposarcoma (PMID: 36674856, PMID: 35074968, PMID: 18500263, PMID: 33799733). 33799733 36674856 35074968 18500263
MDM2 amp parosteal osteosarcoma not applicable N/A Clinical Study Diagnostic MDM2 amplification aids in the diagnosis of parosteal osteosarcoma (PMID: 33799733, PMID: 24786129, PMID: 21336260, PMID: 20601938). 20601938 33799733 24786129 21336260